Myocardial toxicity is the most important life-limiting complication of iron overload. Research on myocardial iron toxicity has been seriously hindered by the lack of a satisfactory experimental model. We have previously shown that iron-loading of cultured rat heart cells results in abnormal contractility and electrophysiologic behaviour and increased peroxidation of membrane lipids, reversible by deferoxamine treatment. In the next phase of our studies we intend to clarify the relation between structural alterations in membrane lipid architecture and the functional abnormalities induced by iron toxicity. These studies will proceed along 3 lines: I. Structural changes in lipid membranes isolated from the sarcolemma, mitochondria and lysosomes will be characterized by measuring their phospholipid, lysophospholipid, phosphatidyl ethanolamine/phosphatidyl choline content, and by identifying membrane lipid moieties in direct contact with the external environment and accessible for radioiodinationor interaction with the with trinitrobenzene sulphonate. II. Abnormal organelle function will be documented in (a) the sarcolemma by measuring transmembrane potential and calcium uptake; (b) in mitochondria by measuring ADP-stimulated and ADP- limited respiration and respiratory control ratio, and; (c) in lysosomes by measuring their fragility documented by latent and sedimentable acid hydrolase activities. III. The ability of ascorbate, alpha-tocopherol, hypoxia and deferozamine to modify or prevent the iron-induced abnormalities will be explored. Abnormalities in organelle function will be correlated with alterations in membrane architecture. The primary target of iron toxicity will be identified by the timing and extent of structural or functional abnormalities observed in the various organelles obtained from iron loaded heart cells. Information gained in these studies will help in clarifying the pathogenesis of mypocardial disease in iron overload, the manner in which hypoxia, iron chelating agents and antioxidants may modify or prevent iron-induced damage to the heart, and may be useful in developing more rational and effective methods for the management of transfusional iron overload.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL034062-06
Application #
3346637
Study Section
Metallobiochemistry Study Section (BMT)
Project Start
1986-07-01
Project End
1993-09-29
Budget Start
1991-09-30
Budget End
1993-09-29
Support Year
6
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Hebrew University of Jerusalem
Department
Type
DUNS #
600044978
City
Jerusalem
State
Country
Israel
Zip Code
91904
Link, G; Pinson, A; Hershko, C (1993) Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. J Lab Clin Med 121:127-34
Hershko, C; Link, G; Tzahor, M et al. (1993) Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J Lab Clin Med 122:245-51
Hershko, C; Link, G; Tzahor, M et al. (1993) The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk Lymphoma 11:207-14
Hershko, C (1992) Iron chelators in medicine. Mol Aspects Med 13:113-65
Shiloh, H; Iancu, T C; Bauminger, E R et al. (1992) Deferoxamine-induced iron mobilization and redistribution of myocardial iron in cultured rat heart cells: studies of the chelatable iron pool by electron microscopy and Mossbauer spectroscopy. J Lab Clin Med 119:428-36
Zevin, S; Link, G; Grady, R W et al. (1992) Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores. Blood 79:248-53
Link, G; Athias, P; Grynberg, A et al. (1991) Iron loading modifies beta-adrenergic responsiveness in cultured ventricular myocytes. Cardioscience 2:185-8
Hershko, C; Link, G; Pinson, A et al. (1991) Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: studies in rat heart cells in culture. Blood 77:2049-53
Grady, R W; Hershko, C (1990) An evaluation of the potential of HBED as an orally effective iron-chelating drug. Semin Hematol 27:105-11
Hershko, C; Pinson, A; Link, G (1990) Iron chelation. Blood Rev 4:1-8

Showing the most recent 10 out of 23 publications